ArticleWorld journal of gastroenterology2007
Development of ulcerative colitis in a patient with multiple sclerosis following treatment with interferon beta 1a.
Article in World journal of gastroenterology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 35 citations in OpenAlex.
- Interferon beta-1a for the maintenance of remission in patients with Crohn's disease: results of a phase II dose-finding study.BMC gastroenterology · 2009Trial
- Adverse side effects of Glatiramer acetate and Interferon beta-1a in patients with multiple sclerosis: A systematic review of case reports.Current journal of neurology · 2023Article
- Ozanimod Therapy in a Patient With Ulcerative Colitis and Multiple Sclerosis: Hitting 2 Birds With 1 Stone.ACG case reports journal · 2023Article
- Multiple Sclerosis and Autoimmune Comorbidities.Journal of personalized medicine · 2022Review
- Treatment approaches to patients with multiple sclerosis and coexisting autoimmune disorders.Therapeutic advances in neurological disorders · 2021Review
- Induction or aggravation of other immune-mediated disorders by disease-modifying therapy in treatment of multiple sclerosis.Iranian journal of neurology · 2018Review
- A case of lower digestive tract hemorrhage caused by appendicitis in China.International journal of surgery case reports · 2017Article
- Type I IFN induces protein ISGylation to enhance cytokine expression and augments colonic inflammation.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- Pro-Inflammatory Signaling by IL-10 and IL-22: Bad Habit Stirred Up by Interferons?Frontiers in immunology · 2013Article
- Immunomodulatory functions of type I interferons.Nature reviews. Immunology · 2012Review
- Article
- Localized delivery of interferon-β by Lactobacillus exacerbates experimental colitis.PloS one · 2011Article
- Delayed resolution of acute inflammation in ulcerative colitis is associated with elevated cytokine release downstream of TLR4.PloS one · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To alert clinicians to a potential novel adverse drug effect of interferon beta 1a, we herein report a patient with relapsing-remitting multiple sclerosis who developed ulcerative colitis following treatment with interferon beta 1a. Ulcerative colitis persisted despite discontinuation of interferon beta 1a treatment and switching the patient to glatiramer acetate. Tacrolimus (FK506), 6-mercaptopurine, and prednisolone were required to induce remission. Both ulcerative colitis and multiple sclerosis were eventually well controlled using this regimen. Our report underscores that caution should be exercised when prescribing immunostimulatory agents in patients with inflammatory bowel disease (IBD) and challenges current efforts to stimulate innate immunity as a novel therapeutic concept for IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.